Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2011 Apr;32(4):537-42.
doi: 10.1038/aps.2010.236. Epub 2011 Mar 14.

A comparison of androgen deprivation therapy versus surgical castration for patients with advanced prostatic carcinoma

Yu-hsiang Lin  1 , Chien-lun Chen, Chen-pang Hou, Phei-lang Chang, Ke-hung Tsui
Affiliations
Comparative Study

A comparison of androgen deprivation therapy versus surgical castration for patients with advanced prostatic carcinoma

Yu-hsiang Lin et al. Acta Pharmacol Sin. 2011 Apr.

Abstract

Aim: To examine the outcomes of patients with advanced prostate carcinoma who underwent medical or surgical castration.

Methods: A hundred twenty one consecutive cases of patients with advanced prostate carcinoma who underwent medical or surgical castration between 2001 and 2006 were retrospectively reviewed. Associations between clinical outcomes and prognostic scoring factors were determined based on the Reijke study. In the surgical and medical castration groups, the impact on the prostate-specific antigen (PSA) normalization rate, the rebound rate and the disease-free survival rate were evaluated. The mean follow-up was 36.1 months.

Results: In the initial 12 months, there were no statistical differences in the PSA normalization rate and the PSA rebound rate between the two groups. However, the PSA rebound rate after the 12th month (20.90% vs 40.74%, P=0.0175) and the 18th month PSA normalization rate (59.70% vs 37.04%, P=0.0217) differed significantly between the two groups, and these differences were maintained to the end of the study. When comparing patients grouped according to Reijke prognosis scores, there was no difference between medical and surgical castration for the good prognosis group. However, among the patients given a poor prognosis, surgical castration was superior in terms of the PSA normalization rate, the PSA rebound rate, the tumor progression-free survival rate (P<0.001) and the overall survival rate (P<0.001).

Conclusion: Advanced prostate carcinoma patients with poor pretreatment prognosis scores should undergo surgical castration rather than medical castration for better PSA rebound rates and overall survival.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Cancer-specific survival based on overall good and poor prognosis groups.
Figure 2
Figure 2
Tumor progression–free survival rate by group.
Figure 3
Figure 3
The overall survival rates by group.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Stamey T, Yang N, Hay A, McNeal J, Freiha F, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987;317:909–16. - PubMed
    1. Wang MC, Valenzuela LA, Murphy GP, Chu TM. Purification of a human prostate specific antigen. Invest Urol. 1979;17:159–63. - PubMed
    1. Loblaw DA, Virgo KS, Nam R, Somerfield MR, Ben-Josef E, Mendelson DS, et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2007 Update of an American Society of Clinical Oncology Practice Guideline. J Clin Oncol. 2007;25:1596–605. - PubMed
    1. Huggins C, Hodges CV. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941;1:293–7. - PubMed
    1. Studer UE, Collette L, Whelan P, Albrecht W, Casselman J, de Reijke T, et al. Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891) Eur Urol. 2008;53:941–9. - PubMed

Publication types